KALV KalVista Pharmaceuticals Inc.

13.29
-0.67  -5%
Previous Close 13.96
Open 13.46
Price To Book 2.42
Market Cap 237,015,535
Shares 17,834,126
Volume 47,309
Short Ratio
Av. Daily Volume 111,997
Stock charts supplied by TradingView

NewsSee all news

  1. KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will

  2. KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs

    – Merck Option Agreement Expires – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease

  3. KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

    – KVD900 Phase 2 Clinical Trial Data Anticipated in Q2 2020 – – KVD824 Selected for Prophylactic Treatment; Phase 2 Expected to Initiate in H2 2020 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage

  4. KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema

    – KVD001 Does Not Meet Primary Endpoint – – Pre-Planned Analyses Show Clinical Benefit on Vision – – KVD001 Generally Safe and Well Tolerated – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage

  5. KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

    – KVD900 Phase 2 Trial Data for On-Demand Treatment of HAE Expected in 2020 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Data Expected This Month – – KVD900 Receives FDA Fast

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data did not meet primary endpoint - December 9, 2019.
KVD001
Diabetic macular edema (DME)
Phase 2 data due 2Q 2020.
KVD900
Hereditary Angioedema (HAE)
Phase 2 trial to be initiated 2H 2020.
KVD824
Hereditary angioedema

Latest News

  1. KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will

  2. KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs

    – Merck Option Agreement Expires – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease

  3. KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

    – KVD900 Phase 2 Clinical Trial Data Anticipated in Q2 2020 – – KVD824 Selected for Prophylactic Treatment; Phase 2 Expected to Initiate in H2 2020 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage

  4. KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema

    – KVD001 Does Not Meet Primary Endpoint – – Pre-Planned Analyses Show Clinical Benefit on Vision – – KVD001 Generally Safe and Well Tolerated – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage

  5. KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

    – KVD900 Phase 2 Trial Data for On-Demand Treatment of HAE Expected in 2020 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Data Expected This Month – – KVD900 Receives FDA Fast

  6. KalVista Pharmaceuticals Provides Business Update

    – KVD900 Phase 2 Clinical Trial for Treatment of Hereditary Angioedema (HAE) Expected to Complete Enrollment in 2019; Data in 2020 – – KVD001 Phase 2 Clinical Trial Data for Patients with Diabetic Macular Edema (DME)

  7. KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will

  8. KalVista Pharmaceuticals Reports Fiscal First Quarter Results

    – Phase 2 Clinical Trial of KVD900 for On-Demand Oral Treatment of Hereditary Angioedema (HAE) Attacks Expected to Complete in Late 2019 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME)